Aadi Bioscience Stock Price, News & Analysis

Aadi Bioscience, Inc. (Nasdaq: AADI) is a precision oncology company in the pharmaceutical preparation manufacturing industry. According to company disclosures, Aadi focuses on applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. The company is described as an oncology therapeutics organization that applies advanced technologies to established tumor biology to deliver advances in cancer treatment.

Business focus and therapeutic area

Aadi identifies itself as a precision oncology company with a vision to make bold choices in how it develops and advances cancer treatments. Its work centers on therapies for difficult-to-treat cancers, reflecting an emphasis on targeted approaches rather than broad, non-specific treatments. The company has highlighted both commercial-stage and preclinical-stage activities in oncology.

In earlier communications, Aadi stated that it was focused on the commercialization of FYARRO® (sirolimus protein-bound particles for injectable suspension) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), a rare and aggressive cancer. FYARRO has been described as the only preferred treatment for patients with advanced malignant PEComa in those disclosures.

Strategic transformation and pipeline evolution

Aadi has outlined a strategic plan that represents a significant transformation of its business. The company announced that it entered into an agreement for the sale of FYARRO and its associated infrastructure to KAKEN Pharmaceutical Co., Ltd. for cash consideration, with KAKEN expected to acquire Aadi Subsidiary, Inc. and all of its assets related to the FYARRO business. Upon closing of this transaction, KAKEN will also acquire the rights to the Aadi name and trademark, according to company statements.

In parallel, Aadi announced that it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs). These ADC programs were developed through a collaboration between WuXi Biologics and HANGZHOU DAC Biotechnology. Aadi states that it is granted exclusive rights to certain patents and know-how for three preclinical ADC programs leveraging HANGZHOU DAC's CPT113 linker-payload technology targeting:

• Protein Tyrosine Kinase 7 (PTK7)
• Mucin-16 (MUC16)
• Seizure Related 6 Homolog (SEZ6)

Company materials describe these as a "three-asset ADC portfolio" and refer to them as next-wave ADCs that utilize a highly stable yet cleavable linker delivering a Topoisomerase I inhibitor payload. Aadi has indicated that these assets were selected based on tumor targets that are upregulated in high-potential cancer indications and where clinical efficacy has been demonstrated by first-generation ADCs.

Historical focus on FYARRO and PEComa

Before announcing the planned divestiture of FYARRO, Aadi reported that it was focused on the commercialization of FYARRO for adult patients with locally advanced unresectable or metastatic malignant PEComa. Company updates have highlighted FYARRO net product sales and described the product as delivering sales growth and demand in its approved indication.

Aadi also previously conducted development activities around nab-sirolimus (the active component in FYARRO) in additional indications. For example, the company disclosed the PRECISION1 tumor-agnostic trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. Aadi later announced that this trial would be halted after an analysis indicated it was unlikely to meet an efficacy threshold necessary to support accelerated approval in that broad indication. The company also referenced Phase 2 trials of nab-sirolimus in advanced or recurrent endometrioid-type endometrial cancer and neuroendocrine tumors, which were adjusted as part of efforts to preserve cash.

Capital strategy and financing

Aadi has described a capital strategy connected to its transformation. The company announced a private investment in public equity (PIPE) financing expected to result in gross proceeds of approximately $100 million, subject to stockholder approval and closing conditions. A subsequent press release reported the closing of this PIPE financing, noting that Aadi sold and issued shares of common stock and pre-funded warrants to institutional and accredited investors in a private placement.

Company communications state that the proceeds from the PIPE financing, together with the sale of the FYARRO business and existing cash, cash equivalents and marketable securities, are expected to fund operations into a multi-year period, including anticipated clinical data readouts for the ADC portfolio. These statements are presented by the company as forward-looking expectations.

Corporate governance and stockholder approvals

Aadi has reported that it filed a definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its strategic plan. The proxy materials and related communications describe proposals submitted to stockholders, including:

• Approval of the sale of FYARRO and associated infrastructure to KAKEN via the sale of Aadi Subsidiary, Inc.
• Approval of the PIPE financing, including the issuance of common stock and pre-funded warrants.
• An amendment to the company’s equity incentive plan to increase the share reserve and adjust the automatic annual share increase.
• A non-binding advisory vote on certain compensation arrangements related to the divestiture.

A subsequent announcement stated that stockholders approved all proposals at a Special Meeting of Stockholders held on February 28, 2025. The company indicated that final voting results would be included in a Form 8-K filed with the SEC.

Research and leadership focus on ADCs

In connection with its new ADC-focused strategy, Aadi has highlighted the addition of leadership with experience in antibody-drug conjugates. The company announced the appointment of a Chief Scientific Officer with extensive ADC expertise and referenced board members with backgrounds at ADC-focused companies. These disclosures are presented by Aadi as supporting its effort to advance its in-licensed ADC portfolio targeting PTK7, MUC16 and SEZ6.

Company statements describe the ADC field as undergoing a transformation and position Aadi’s approach as using a tumor-targeting strategy that utilizes a next-generation linker-payload platform. Aadi has characterized its ADC pipeline as having the potential to address cancers where the selected targets are often overexpressed and where there is significant unmet therapeutic need.

Exchange listing and sector

Aadi Bioscience’s common stock trades on Nasdaq under the ticker symbol AADI. Based on the provided classification, the company operates within the pharmaceutical preparation manufacturing industry in the broader manufacturing sector. Company press releases identify locations such as Los Angeles and Morristown, New Jersey, in connection with corporate updates and events.

Company status

The available information includes multiple press releases through 2025 that refer to Aadi as an ongoing public company, describe a continuing strategic plan, and reference upcoming webcasts and financial results. There is no explicit indication in the provided materials of a completed merger, liquidation, bankruptcy filing, or delisting of Aadi’s common stock. The company has, however, described a significant transformation of its business, including the planned sale of its FYARRO business and the in-licensing of a new ADC portfolio.

FAQs about Aadi Bioscience (AADI)

• What does Aadi Bioscience do?
  Aadi Bioscience describes itself as a precision oncology company focused on applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. It has been characterized as an oncology therapeutics company applying advanced technologies to established tumor biology.
• What is Aadi Bioscience’s stock symbol and exchange?
  Aadi Bioscience’s common stock trades on Nasdaq under the ticker symbol AADI, according to company press releases.
• What is FYARRO and how is it related to Aadi?
  Company disclosures state that FYARRO (sirolimus protein-bound particles for injectable suspension) is approved for the treatment of adult patients with locally advanced unresectable or metastatic malignant PEComa. Aadi previously focused on the commercialization of FYARRO and has reported product sales from this therapy.
• What change did Aadi announce regarding FYARRO?
  Aadi announced an agreement for KAKEN Pharmaceutical to acquire Aadi Subsidiary, Inc. and all of its assets related to the FYARRO business, including associated infrastructure. Upon closing, KAKEN is also expected to acquire the rights to the Aadi name and trademark, according to the company.
• What is Aadi’s ADC portfolio?
  Aadi reported entering into an exclusive license agreement for a three-asset portfolio of preclinical antibody-drug conjugates developed through a collaboration between WuXi Biologics and HANGZHOU DAC. The portfolio includes ADC programs targeting PTK7, MUC16 and SEZ6 using HANGZHOU DAC’s CPT113 linker-payload technology.
• How is Aadi funding its ADC strategy?
  The company announced a private investment in public equity (PIPE) financing and later reported the closing of this private placement, in which it sold common stock and pre-funded warrants to institutional and accredited investors. Aadi has stated that the proceeds from the PIPE financing, together with the sale of the FYARRO business and existing cash resources, are expected to fund operations for several years, including anticipated clinical data for the ADC portfolio.
• What was the PRECISION1 trial?
  Aadi described PRECISION1 as a tumor-agnostic trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. The company later announced that the trial would be halted after an independent committee analysis indicated it was unlikely to meet the efficacy threshold needed to support accelerated approval in that broad indication.
• Is Aadi still focused on FYARRO?
  Earlier disclosures emphasized Aadi’s focus on FYARRO commercialization for malignant PEComa. More recent communications describe a strategic plan centered on selling the FYARRO business and shifting toward an in-licensed ADC portfolio. The company has presented this as a business transformation aimed at revitalizing its product pipeline.
• What sector and industry is Aadi part of?
  Based on the provided classification, Aadi operates in the pharmaceutical preparation manufacturing industry within the manufacturing sector, and its activities are focused on oncology therapeutics.
• Where can investors find more information about Aadi’s plans?
  Aadi has indicated that it files proxy statements and other documents with the U.S. Securities and Exchange Commission in connection with its strategic transactions and that details about proposals and transactions are included in those filings. The company also references an "Investors & News" section where it posts updates and webcasts.